Thomas Edward Schoenherr sells 10,281 Tempus AI shares at $85 each, totaling $873,885

Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, Inc., sold 10,281 shares of the company on September 30, 2026, at $85.00 per share, totaling $873,885.

Who is Thomas Edward Schoenherr and what is his actual role at Tempus AI, Inc.

Thomas Edward Schoenherr serves as the Chief Executive Officer – Diagnostics at Tempus AI, Inc., a publicly traded company under the ticker TEM, specializing in artificial intelligence applications for healthcare. In this role, he oversees product strategy, leads clinical research teams, and deploys genomic data analysis solutions. His position places him at the center of decisions regarding partnerships with laboratories, clinical trials, and regulatory validation protocols.

The role of CEO of Diagnostics involves daily access to non-public information, including trial results, revenue forecasts for new services, and major contract negotiations with medical sector players. This information can influence market perceptions of the company's growth prospects and is therefore considered material under U.S. securities regulations.

Transaction details: 10,281 shares at $85.00 each

The Form 4 filed on September 30, 2026, indicates that 10,281 shares of Tempus AI, Inc. were sold at $85.00 per share. The gross value of the transaction amounts to $873,885, calculated by multiplying the number of shares by the per-unit price. No other securities were mentioned in the same filing, suggesting that the sale pertains exclusively to common shares held by the insider.

The filing specifies that the transaction was executed through a direct sale, with no indication of being part of an option plan or stock buyback program. The $85.00 price reflects the market value of the share on the transaction date, as recorded on the U.S. stock exchanges where TEM is listed.

Why insiders sell their shares – possible reasons

Executives may decide to liquidate a portion of their shares to diversify their personal portfolio, reduce exposure to a single company, or meet immediate liquidity needs. The sale may also be motivated by tax planning, such as realizing capital gains before the end of the fiscal year.

In some cases, the sale may reflect the desire to fund personal projects, such as purchasing real estate or settling family obligations. It is also possible that the transaction falls under a pre-established sell plan, authorized by the company, allowing executives to regularly dispose of a portion of their shares without signaling disengagement from the business.

How individual investors follow Form 4 filings

Form 4 filings are published on the SEC's EDGAR platform and are freely accessible to all users. Investors can review the original document via the URL https://www.sec.gov/Archives/edgar/data/2113721/000211372126000018/0002113721-26-000018-index.htm, where each field of the filing is presented in a readable table format.

Data aggregators, such as WhaleWisdom or OpenInsider, offer filters to track executives' buys and sells for a specific company. These tools provide the ability to receive real-time alerts when a new Form 4 is filed, facilitating quick updates to portfolios. However, the information in a Form 4 reflects only a single transaction and does not, on its own, allow for predicting future stock price movements.